Amgen Gets FDA Approval On Prolia

Thousand Oaks-based Amgen said Tuesday evening that it has received U.S. Food and Drug Administration (FDA) approval on its pRolia treatment of osteoporosis for postmenopausal women. The firm said the approval was based on its Phase 3 study, which involved over 7,808 women in a three year study. Amgen said it has been working on the compouond for more than 15 years, when it first discovered an essential pathway that regulates bone metabolism.